Immuron (IMRN) Struggles After Announcing Trial Results
Immuron Limited (NASDAQ:IMRN) is a biotechnology company that provides a medicine to prevent diarrhea and is also developing similar medicines.
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Citadel Investment Group Ken Griffin | 13,804 | $10,695 | -70% | 0% |
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 30,574 | $23,689 | 0% | |
| 2. | 17,383 | $13,468 | 0% | |
| 3. | 10,906 | $8,450 | 0% | |
| 4. | 7,367 | $5,708 | 0% | |
| 5. | 4,600 | $3,564 | 0% |